Bayview Pharmacy is pleased to present a specially compounded oral suspension formulation that combines Montelukast 1 mg/ml, Ketotifen 0.5 mg/ml, Budesonide 0.5 mg/ml, and Quercetin Dihydrate 10 mg/ml. This unique formulation is designed to address a range of disease states, including asthma, allergic rhinitis, and chronic urticaria.

Montelukast, a leukotriene receptor antagonist, works to reduce inflammation and airway constriction associated with asthma. Ketotifen, an antihistamine, aids in alleviating symptoms of allergic rhinitis such as sneezing, itching, and a runny nose. Budesonide, a corticosteroid, also helps to reduce inflammation and airway constriction in asthma patients. Lastly, Quercetin Dihydrate, a flavonoid, assists in reducing inflammation and histamine release associated with chronic urticaria.

This compounded formulation is a homogeneous mixture, where all the ingredients are uniformly dispersed throughout a liquid medium. This ensures that each dose administered is consistent and provides the intended therapeutic effect. The liquid dosage form is easy to administer, making it a convenient treatment option for patients of all ages.

Furthermore, this formulation is designed to minimize side effects, enhancing patient comfort and adherence to treatment. If you have any questions about this formulation or how it can help manage your condition, please do not hesitate to contact us at Bayview Pharmacy. Our team is committed to providing comprehensive care and support to all our patients.

Montelukast, ketotifen, budesonide, and quercetin dihydrate are combined in a liquid dosage form to treat conditions such as asthma, allergic rhinitis, and chronic obstructive pulmonary disease (COPD). Each of these ingredients plays a crucial role in managing these conditions. Montelukast is an anti-inflammatory agent that blocks leukotrienes, substances that cause inflammation in the airways. Ketotifen, an antihistamine, works by blocking histamine, another substance that causes inflammation in the airways. Budesonide, a corticosteroid, reduces inflammation in the airways. Quercetin dihydrate, a flavonoid, reduces inflammation and improves airway function. This combination of medications can help reduce symptoms such as wheezing, coughing, and difficulty breathing.

Patients should be aware that this combination of medications may cause side effects, including nausea, headache, dizziness, and insomnia. It's also important to note that these medications may interact with other drugs, such as anticoagulants, diuretics, and immunosuppressants. Therefore, patients should inform their healthcare provider of all medications they are currently taking before starting this treatment.

Healthcare providers prescribing this combination should be aware of potential drug interactions and monitor patients for any adverse reactions. They should also monitor for signs of side effects. If you have any questions about this formulation or potential interactions with other medications, please consult with your healthcare provider.

Montelukast 1 mg/ml/Ketotifen 0.5 mg/ml/Budesonide 0.5 mg/ml/Quercetin Dihydrate 10 mg/ml Oral Suspension is a compounded medication designed to address a range of conditions. This formulation combines the anti-inflammatory properties of Montelukast, typically used in the treatment of asthma, allergic rhinitis, and chronic obstructive pulmonary disease (COPD), with the antihistamine effects of Ketotifen, which is commonly used to manage allergic rhinitis, asthma, and other allergic conditions.

Additionally, this formulation includes Budesonide, a corticosteroid used to treat asthma, allergic rhinitis, and COPD. The final component, Quercetin Dihydrate, is a flavonoid that is used to manage allergies, asthma, and other inflammatory conditions. Together, these ingredients work synergistically to reduce inflammation in the airways, decrease the production of histamine, and reduce the production of inflammatory mediators, thereby alleviating the symptoms of asthma, allergic rhinitis, and COPD.

This oral suspension is typically administered once or twice daily, as directed by a healthcare provider. It is crucial to shake the suspension well before each use to ensure the ingredients are uniformly dispersed throughout the liquid medium. The suspension should be stored at room temperature and should not be frozen to maintain its efficacy and stability.

If you have any questions about this medication, its components, or its mechanism of action, please do not hesitate to reach out. It's important to understand your medications and how they work to manage your health effectively.

This compounded formulation of Montelukast 1 mg/ml, Ketotifen 0.5 mg/ml, Budesonide 0.5 mg/ml, and Quercetin Dihydrate 10 mg/ml is presented as an oral suspension. It is a liquid dosage form where the active ingredients are uniformly dispersed throughout a liquid medium, ensuring a homogeneous mixture for administration. This formulation is primarily indicated for the treatment of various respiratory and allergic conditions including asthma, allergic rhinitis, chronic urticaria, eosinophilic esophagitis, and bronchopulmonary dysplasia.

It has been found effective in reducing inflammation and improving airway function, thereby potentially reducing the risk of exacerbations and enhancing the quality of life for patients. This formulation may also be beneficial in reducing the risk of developing asthma-related complications, such as bronchitis and pneumonia. Furthermore, it may be used to mitigate the risk of developing allergies and other allergic reactions.

While this formulation is primarily used for the aforementioned conditions, it may also be used to treat other conditions as determined by your healthcare provider. If you have any questions about the use of this formulation, please consult with your healthcare provider to ensure it is the right treatment for your specific needs.